logo

KILITCH vs KREBSBIO: Stock Comparison

KILITCH DRUGS INDIA vs KREBS BIOCHEMICALS & INDUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

KILITCH DRUGS INDIA is the larger company by market capitalisation. KILITCH DRUGS INDIA shows faster revenue growth, a higher ROCE and a higher net margin, while KREBS BIOCHEMICALS & IND shows a lower P/E. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

KILITCH leads 6; KREBSBIO leads 2 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

KILITCHKREBSBIO

Valuation lens

What price are you paying?

Market CapContext only
₹668 Cr
₹125 Cr
P/E RatioKREBSBIO has the lower reading
26.1x
0x ✓
P/B RatioKREBSBIO has the lower reading
2.81x
0x ✓
EPSKILITCH has the higher reading
₹0.83 ✓
₹-1.15
Book ValueContext only
₹79.19
—
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
KILITCH is the larger company
₹668 Cr vs ₹125 Cr
P/E Ratio
KREBSBIO has a lower P/E
0x vs 26.1x
P/B Ratio
KREBSBIO has a lower P/B
0x vs 2.81x
EPS
KILITCH has higher earnings per share
₹0.83 vs ₹-1.15
Revenue Growth (TTM YoY)
KILITCH has faster revenue growth
46.3% vs 11.6%
EPS Growth (TTM YoY)
KILITCH has faster EPS growth
26.5% vs 0%
ROCE
KILITCH has a higher ROCE
7.73% vs -15.89%
Net Margin
KILITCH has a higher net margin
12.81% vs -71.35%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKILITCHKREBSBIO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricKILITCHKREBSBIO
Live Price₹202.11₹57.48
Day Change-0.82%2.53%
Volume68,2063,570
52-Week High₹439₹76.85
52-Week Low₹117.25₹38.33
Distance from 52W High-53.96%-25.2%

Valuation

MetricKILITCHKREBSBIO
Market Cap₹668 Cr₹125 Cr
P/E Ratio26.1x0x
P/B Ratio2.81x0x
EPS₹0.83₹-1.15
Book Value₹79.19—
Dividend Yield0%0%

Growth

MetricKILITCHKREBSBIO
Revenue Growth (TTM YoY)46.3%11.6%
EPS Growth (TTM YoY)26.5%0%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricKILITCHKREBSBIO
ROE9.73%—
ROCE7.73%-15.89%
Net Margin12.81%-71.35%
Operating Margin23.33%-41.49%
Debt to Equity0.27x—

Shareholding

As of Sep 2026 • change vs previous quarter
MetricKILITCHKREBSBIO
Promoter Holding63.77%72.74%
FII Holding0.11%▼ 0.01 pp0.5%
DII Holding0.5%▲ 0.5 pp0%
Public Holding35.62%▼ 0.49 pp26.76%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KILITCH DRUGS INDIA and KREBS BIOCHEMICALS & IND.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.